Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
